The progressive development of poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) has revolutionised the management of patients with high-grade serous ovarian carcinoma (HGSOC). This evidence concerns the gene PARP1 and ovarian serous carcinoma.